翔宇醫療(688626.SH):將加大AI+康復器械、人工智能、康復機器人、腦機接口方向的研發投入
格隆匯3月14日丨翔宇醫療(688626.SH)在投資者互動平台表示,公司始終秉承“科技創新支撐,產學研用一體,引領康復未來”的發展理念,在AI技術方面,公司掌握多項自主創新的核心技術,包括圖像深度學習算法、機器人智能控制算法等。例如,通過圖像深度學習算法,對人體姿態識別,智能分析人體姿態活動度;通過醫學影像識別與機器臂協同控制技術,實現理療類設備智能化治療。公司現有經顱磁AI導航機器人、團體生物反饋治療儀、肌電生物反饋治療系統、智能矯正鏡等是應用以上技術的代表產品,後續還將加大AI+康復器械、人工智能、康復機器人、腦機接口方向的研發投入,陸續推出滿足B端及C端市場需求的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.